Focus on Rapid Delivery Zosano Pharma specializes in transdermal drug delivery systems designed for rapid symptom relief, offering a unique value proposition for healthcare providers seeking fast-acting treatments, which presents a significant opportunity to expand in acute care markets.

Potential for Market Expansion With an emphasis on improving ease of use and stability over traditional oral or injectable formulations, Zosano’s technology addresses unmet needs across large patient populations, creating ample opportunities to partner with pharmaceutical companies looking to enhance existing therapeutics.

Recent Asset Acquisition The sale of Zosano’s assets to Emergex Vaccines in 2022 indicates a strategic pivot, suggesting potential collaboration or licensing opportunities in vaccine delivery or novel therapeutics within emerging vaccine markets.

Growing Financial Footprint Having secured significant funding and revenue in the recent period, Zosano presents a financially stable partner for joint ventures or licensing deals focused on innovative transdermal solutions in the CNS and vaccine sectors.

Advanced Technological Infrastructure Utilizing modern cloud-based platforms and analytics tools, Zosano is positioned to adopt or integrate cutting-edge digital health innovations, offering opportunities to enhance drug delivery systems with integrated monitoring or telehealth solutions.